TP53 and neoplasm: Although not statistically significant, we found the frequency of TP53 mutations to be much higher within the subset of BRCA1 methylated tumours compared with the non-methylated BRCA1 tumours or 38.5% (5/13) compared to 17.2% (22/128), respectively (P = 0.1299, OR = 3.0, 95%CI = 0.9–10.1; Table 1).